Welcome to our dedicated page for Health In Tech SEC filings (Ticker: HIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Health In Tech, Inc. filings document material-event disclosures for a Nevada operating company with Class A common stock listed on the Nasdaq Capital Market under HIT. Recent Form 8-K reports cover results of operations and financial condition, Regulation FD materials, investor presentations and conference-call transcripts.
The filing record also addresses capital-structure matters, including a private investment in public equity financing, and governance disclosures involving executive officer departures, compensatory arrangements and related consulting agreements. The company identifies as an emerging growth company in its Exchange Act reports.
Health In Tech, Inc. (HIT) reported that director Timothy Hayes sold Class A Common Stock in two recent transactions. On September 11, 2026 he sold 12,000 shares at $0.91 per share, and on September 9, 2026 he sold 5,730 shares at $0.93 per share, for total reported sales of 17,730 shares, all held directly. No Rule 10b5-1 trading plan is reported for these sales, and the filing does not state his remaining shareholdings.
Health In Tech, Inc. (HIT) insider Hasan Zain Syed, identified as Chief Growth Officer, has filed a notice of intent to sell up to 18,334 shares of common stock under Rule 144. The planned sales, with an aggregate market value of $17,169.79, may begin on or about September 11, 2026, through APEX CLEARING on the Nasdaq Stock Market and will be executed pursuant to a Rule 10b5-1 trading plan.
Health In Tech, Inc. (HIT) filed a shelf registration to permit YA II PN, LTD (Yorkville) to resell up to 29,532,889 shares of its Class A common stock that may be issued under a Standby Equity Purchase Agreement (SEPA) and related Convertible Notes. The registration covers 9,532,889 Conversion Shares issuable upon note conversions and 20,000,000 Advance Shares issuable through equity advances. Health In Tech will not receive proceeds from Yorkville’s resale of these shares, but may receive up to $14.25 million from Convertible Notes and up to $20.0 million from share sales to Yorkville under the SEPA, with initial proceeds used to repay the notes. As of September 2, 2026, shares outstanding were 53,702,649, and Nasdaq rules impose a 13,100,378‑share Exchange Cap and a 4.99% Beneficial Ownership Limitation, so additional issuances would require stockholder approval. The company describes significant potential dilution to existing holders and expects longer‑term SEPA proceeds, once available beyond note repayment, to support sales expansion, technology and product development, and working capital.
Health In Tech, Inc. director and Chief Financial Officer Qian LinLin reported a disposition of Class A Common Stock related to tax withholding. On 2026-08-13, 28,183 shares of Class A Common Stock were surrendered to the company at $1.06 per share to satisfy tax withholding and remittance obligations arising from the vesting of previously granted restricted shares. After this transaction, Qian LinLin directly holds 8,998,392 Class A Common Stock, consisting of 938,743 restricted shares and 8,059,649 unrestricted shares. The reported total excludes 2,700,000 shares of Class B Common Stock and 711,510 options to purchase Class A Common Stock.
Health In Tech, Inc. director and Chief Executive Officer Tim Donald Johnson reported a code F transaction involving restricted Class A Common Stock. On 2026-08-13, 46,327 shares of Class A Common Stock were surrendered to the company at $1.06 per share to satisfy tax withholding and remittance obligations arising from the vesting of restricted shares.
After this withholding transaction, Johnson directly holds 23,334,365 Class A shares, consisting of 842,491 restricted and 22,491,874 unrestricted Class A shares. In addition, the disclosure notes that this figure excludes 9,000,000 shares of Class B Common Stock and 734,707 options to purchase Class A Common Stock.
Health In Tech, Inc. officer Hasan Zain Syed reported a disposition of 4,007 shares of Class A Common Stock on 2026-08-13 at $1.06 per share. The shares were surrendered to cover tax withholding related to vesting of previously granted restricted stock. After this tax-withholding disposition, Syed directly holds 200,211 shares, including 179,326 restricted and 20,885 unrestricted shares of Class A Common Stock.
Health In Tech, Inc. reported second quarter 2026 revenue of $8.1 million, down from $9.3 million a year earlier, primarily due to policy effective dates shifting while onboarding a new carrier. For the first half of 2026, revenue was $16.8 million versus $17.3 million in the prior-year period.
Management emphasized “contracted revenue” and “pipeline revenue” as leading indicators. Contracted revenue for the first half totaled $32.3 million, of which $17.3 million has already been recognized, with $14.0 million expected in the second half of 2026 and $1.0 million in 2027. Pipeline revenue was $66.3 million as of July 31, with an expected conversion rate of 15%–40%, supporting reaffirmed full-year 2026 revenue guidance of $45–$50 million.
Profitability weakened as the company invested in sales, marketing and technology. Adjusted EBITDA was $(1.3) million for the quarter and $(2.6) million for the first half, compared with positive results a year ago. Net loss was $(2.5) million in Q2 and $(4.1) million for the first half. Distribution partners grew to 933, up 19.9% year over year. Health In Tech ended the quarter with $6.5 million in cash and $11.8 million in working capital, and highlighted upcoming launches such as the HitRix marketplace and its Three-Year Rate Stabilization Program.
Health In Tech, Inc., an AI-driven marketplace for self-funded health plans for small and mid-sized businesses, furnished an investor presentation outlining its business model, market opportunity and recent financial performance. The company earns primarily fee-based revenue from self-funded plan administration and carrier underwriting, while stating it has no plan or underwriting risk exposure.
The presentation reaffirms 2026 revenue guidance of $45–$50 million, versus 2025 revenue of $33.3 million, supported by $32 million of contracted revenue from first-half 2026 activity and $66 million of pipeline revenue as of July 31, 2026. For Q2 2026, revenue was $8.1 million with a gross margin of 48.7%, compared with $9.3 million and 67.7% a year earlier, and the company reported a net loss and negative Adjusted EBITDA. Cash, working capital and stockholders’ equity all increased between June 30, 2025 and June 30, 2026. The company also highlights broker and partner growth and notes risk factors that include its liquidity position and its ability to continue as a going concern.
Health In Tech, Inc. reported weaker results for the quarter and six months ended June 30, 2026 while reiterating its full-year outlook. For the quarter, total revenues were $8.1 million versus $9.3 million a year earlier, and the company moved from net income of $0.6 million to a net loss of $2.5 million. Gross profit declined to $3.9 million as costs and operating expenses increased, leading to an operating loss and negative Adjusted EBITDA of $1.3 million, compared with positive $1.6 million in the prior-year quarter.
For the first half of 2026, revenues were $16.8 million compared with $17.3 million in 2025, with a net loss of $4.1 million versus net income of $1.1 million. Operating cash flow was an outflow of $6.2 million. As of June 30, 2026, the company reported $32.3 million in Contracted Revenue and cash and cash equivalents of $6.5 million; total assets rose to $29.6 million and stockholders’ equity to $19.6 million, aided by a recent PIPE financing.
As of July 31, 2026, Pipeline Revenue totaled $66.3 million, including $64.4 million in quoting or binding stages that management estimates could convert into $3.1 million to $8.3 million of GAAP revenue in 2026 and additional revenue in 2027. Supported by this contracted and pipeline activity, the company reaffirmed its 2026 GAAP revenue guidance of $45 million to $50 million and highlighted strategic initiatives such as its Three-Year Rate Stabilization Program and the planned launch of its HitRix marketplace in the second half of 2026.
Health In Tech, Inc. reported weaker results for the quarter and six months ended June 30, 2026. Total revenues were $8.1 million for the quarter and $16.8 million year-to-date, slightly below the prior-year periods, while cost of revenues rose sharply, compressing margins.
For the quarter, the company recorded a net loss of $2.5 million versus net income of $0.6 million a year earlier; for the first half, it reported a net loss of $4.1 million compared with net income of $1.1 million. Operating expenses increased across sales and marketing, general and administrative, and research and development, and included a $739,773 credit loss on other receivables tied to purchased Deferred Administrative Surplus.
Cash used in operating activities was $6.2 million for the first half of 2026, compared with $2.0 million provided in the prior-year period. The company strengthened liquidity via a March 2026 PIPE financing that raised net proceeds of $6.4 million and ended June with cash and cash equivalents of $6.5 million. A program with a major stop-loss carrier led to cumulative revenue reductions of about $4.0 million and $4.0 million of interim payments, and the carrier has asserted an additional potential adjustment of up to approximately $0.4 million that remains under negotiation.